Accessibility Menu
Kyowa Kirin logo

Kyowa Kirin(OTC) KYKOF

Current Price$14.21
Market Cap$7.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+181%
5 Year-46%
1 Year+1%
1 Month+2%
Kyowa Kirin last closing stock price
MetricPriceDate
Last closeUSD 14.432026-07-13
Kyowa Kirin stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.51%USD 14.212026-06-30
1 month+1.51%USD 14.212026-06-10
3 month-2.7%USD 14.832026-04-13
Year to date-6.38%USD 15.412025-12-31
1 year+0.57%USD 14.342025-07-11
3 year-19.32%USD 17.882023-07-13
5 year-46.49%USD 26.962021-07-01
Since inception+180.71%USD 5.142003-07-31

Kyowa Kirin Financials at a Glance

Market Cap

$7.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥511.75B

Net Income (TTM)

¥73.04B

EPS (TTM)

$0.92

P/E Ratio

15.70

Dividend

$0.42

Beta (Volatility)

0.05 (Low)

Price

$14.21

Volume

56

Open

$14.21

Previous Close

$14.21

Daily Range

$14.21 - $14.21

52-Week Range

$12.42 - $18.00

Estimated Earnings Date

Aug 3, 2026

KYKOF News

m&A

Why Orchard Therapeutics Stock Is Soaring Today

George Budwell, PhDOct 5, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kyowa Kirin

Kyowa Kirin Co., Ltd. is a global pharmaceutical company focused on developing, manufacturing, and commercializing innovative medicines. The company specializes in therapeutic areas such as oncology, nephrology, central nervous system disorders, and immunological conditions.

Products and Services
  • Key oncology products include ABSTRAL and LEUNASE for cancer pain management and leukemia
  • Nephrology offerings include CONIEL and erythropoiesis stimulating agents like ESPO
  • Immunological treatments feature ALLELOCK and LUMICEF for allergies and psoriasis
Growth Outlook
  • Recent partnership with Amgen for co-development of KHK4083 enhances pipeline potential
  • Focus on expanding therapeutic areas supports long-term growth strategy
  • Strong R&D investment of JPY 27.3 billion in Q1 2026 indicates commitment to innovation
Financial Highlights
  • Q1 2026 revenue of JPY 119.2 billion reflects solid market demand
  • Net income of JPY 12.1 billion in Q1 2026 shows strong profitability
  • TTM P/E ratio of 19.1 suggests reasonable valuation compared to industry peers
Kyowa Kirin Co., Ltd. has established itself as a key player in the pharmaceutical industry, with a diverse product portfolio and a commitment to innovation. The company's strategic partnerships and robust R&D investments position it well for future growth. Recent financial performance indicates strong revenue generation and profitability, making it an attractive option for potential investors interested in the healthcare sector.
AI Generated • Jul 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5,161

CEO

Abdul Mullick, PhD

Website

www.kyowakirin.co.jp/index.html

Headquarters

Tokyo, TY 100-0004, JP

KYKOF Financials

Key Financial Metrics (TTM)

Gross Margin

73.30%

Operating Margin

21.54%

Net Income Margin

14.28%

Return on Equity

8.39%

Return on Capital

11.12%

Return on Assets

6.83%

Earnings Yield

6.37%

Dividend Yield

2.91%

Payout Ratio

44.52%

Stock Overview

Market Cap

$7.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

523.49M

Volume

56

Avg. Volume

680.161

Financials (TTM)

Gross Profit

¥376.15B

Operating Income

¥110.17B

EBITDA

¥125.72B

Operating Cash Flow

¥149.75B

Capital Expenditure

-¥41.30B

Free Cash Flow

¥108.45B

Cash & ST Invst.

¥251.09B

Total Debt

¥21.86B

Kyowa Kirin Performance Analysis

Kyowa Kirin annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31JPY 3,028,800,292-5.5%
20232023-12-31JPY 3,145,038,2043.8%
20242024-12-31JPY 3,271,119,9434.0%
20252025-12-31JPY 3,321,040,1671.5%
Kyowa Kirin sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3020.2%
Q32025-09-30-4.3%
Q42025-12-3121.3%
Q12026-03-31-18.4%
Kyowa Kirin annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31JPY 0.76-14.5%
20232023-12-31JPY 1.0741.7%
20242024-12-31JPY 0.75-30.5%
20252025-12-31JPY 0.8614.7%
Kyowa Kirin sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3064.7%
Q32025-09-3062.6%
Q42025-12-31107.5%
Q12026-03-31-65.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

¥119.21B

+13.8%

Gross Profit

¥86.00B

+7.3%

Gross Margin

72.14%

N/A

Market Cap

$7.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.46M

N/A

Employees

5,161

N/A

Net Income

¥12.11B

+96.4%

EBITDA

¥25.04B

+60.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

¥251.09B

+17.1%

Total Debt

¥21.86B

-2.8%

Accounts Receivable

¥121.66B

-10.9%

Inventory

¥65.66B

-10.3%

Long Term Debt

¥21.86B

-2.8%

Short Term Debt

¥0.00

N/A

Return on Assets

6.83%

N/A

Return on Invested Capital

11.92%

N/A

Free Cash Flow

¥44.33B

+1019.3%

Operating Cash Flow

¥56.69B

+665.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ESALFEisai Co., Ltd.
$26.18+0.00%
ESAIYEisai Co., Ltd.
$7.10+2.31%
GIFLFGrifols, S.A.
$10.25+0.00%
OPHLYOno Pharmaceutical Co., Ltd.
$4.93+2.32%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
FFord Motor Company
$14.37+0.02%

Questions About KYKOF

What is the current price of Kyowa Kirin?

Kyowa Kirin is trading at $14.21 per share.

What is the 52-week range for Kyowa Kirin?

Over the past 52 weeks, Kyowa Kirin has traded between $12.42 and $18.00.

How much debt does Kyowa Kirin have?

As of the most recent reporting period, Kyowa Kirin reported total debt of ¥136.55M.

How much cash does Kyowa Kirin have on hand?

Kyowa Kirin reported ¥1.57B in cash and cash equivalents in its most recent financial results.

What is Kyowa Kirin’s dividend yield?

Kyowa Kirin currently has a dividend yield of 2.91%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services